nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.06.2016 | Original Article

Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress

verfasst von: X. Deng, J. Cheng, M. Shen

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

It is well established that the activation of the renin–angiotensin system (RAS) and the oxidative stress caused by hyperglycemia are major mediators of the development and progression of diabetic nephropathy (DN). Vitamin D may be important in maintaining podocyte health, preventing epithelial-to-mesenchymal transformation, and suppressing renin gene expression and inflammation, but its mechanism requires clarification. This study evaluated the specific mechanism of vitamin D to DN improvement.

Methods

We induced a rat model of diabetes with an intraperitoneal injection of streptozotocin (60 mg/kg). The streptozotocin-induced diabetic rats were fed normal chow for about 2 months to induce the DN model. The DN rats were then treated with irbesartan and/or calcitriol, administered intragastrically about 1 month.

Results

The rats displayed the early characteristics of DN, including increased microalbuminuria, obvious hypertrophic kidney, and a markedly increased kidney weight/bodyweight ratio. Vitamin D inhibited the compensatory increase in renin expression. Malondialdehyde, which reflects oxidative stress levels, was elevated in the DN group rats and their antioxidant capacity was significantly reduced. The irbesartan and calcitriol interventions markedly improved the renal pathology and pathophysiological changes. Irbesartan combined with vitamin D (calcitriol) more effectively ameliorated DN than irbesartan alone.

Conclusions

Vitamin D combined with angiotensin II type 1 receptor blockers exerts a synergistic effect on the treatment of DN, not only by inhibiting renin but also by reducing oxidative stress and increasing the renal antioxidant capacity.

Ritz E, Rychlik I, Locatelli F, Halimi S (1999) End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 34:795–808CrossRefPubMed

Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML et al (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164–176CrossRefPubMed

Remuzzi G, Schieppati A, Ruggenenti P (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346:1145–1151CrossRefPubMed

Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH (2000) Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601–606CrossRefPubMed

Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J (2007) Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 24:486–493CrossRefPubMed

Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454CrossRefPubMed

Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878CrossRefPubMed

Li YC, Kong J, Wei M, Chen ZF, Liu SQ et al (2002) 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229–238CrossRefPubMedPubMedCentral

Yuan W, Pan W, Kong J, Zheng W, Szeto FL et al (2007) 1,25-Dihydroxyvitamin D3 Suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282:29821–29830CrossRefPubMed

10.

Li YC (2011) Podocytes as target of vitamin D. Curr Diabetes Rev 7:35–40CrossRefPubMed

11.

Izquierdo MJ, Cavia M, Muñiz P, de Francisco AL, Arias M et al (2012) Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrol 13:159CrossRefPubMedPubMedCentral

12.

Diaz VA, Mainous AG, Carek PJ, Wessell AM, Everett CJ (2009) The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 22:521–527CrossRefPubMed

13.

Zhou QX, Liu F, Zhang JS, Lu JG, Gu ZL et al (2013) Effects of triterpenic acid from Prunella vulgaris L. on glycemia and pancreas in rat model of streptozotozin diabetes. Chin Med J (Engl) 126:1647–1653

14.

Zhang Z, Sun L, Wang Y, Ning G, Minto AW et al (2008) Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 73:163–171CrossRefPubMed

15.

Montilla P, Barcos M, Munoz MC, Bujalance I, Munoz-Castaneda JR et al (2005) Red wine prevents brain oxidative stress and nephropathy in streptozotocin-induced diabetic rats. J Biochem Mol Biol 38:539–544CrossRefPubMed

16.

Raza H, Prabu SK, John A, Avadhani NG (2011) Impaired mitochondrial respiratory functions and oxidative stress in streptozotocin-induced diabetic rats. Int J Mol Sci 12:3133–3147CrossRefPubMedPubMedCentral

17.

Zhang Z, Zhang Y, Ning G, Deb DK, Kong J et al (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105:15896–15901CrossRefPubMedPubMedCentral

18.

Zhang Y, Deb DK, Kong J, Ning G, Wang Y et al (2009) Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 297:F791–F801CrossRefPubMedPubMedCentral

19.

Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S et al (2011) Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Nephron Exp Nephrol 117:e124–e132CrossRefPubMed

20.

Cetinkalp S, Delen Y, Karadeniz M, Yüce G, Yilmaz C (2009) The effect of 1alpha, 25(OH)2D3 vitamin over oxidative stress and biochemical parameters in rats where Type 1 diabetes is formed by streptozotocin. J Diabetes Complications 23:401–408CrossRefPubMed

21.

Singh DK, Winocour P, Farrington K (2011) Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 7:176–184CrossRefPubMed

22.

Takayanagi R, Inoguchi T, Ohnaka K (2011) Clinical and experimental evidence for oxidative stress as an exacerbating factor of diabetes mellitus. J Clin Biochem Nutr 48:72–77CrossRefPubMedPubMedCentral

23.

Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058–1070CrossRefPubMedPubMedCentral

24.

Fujita H, Fujishima H, Morii T, Sakamoto T, Komatsu K et al (2012) Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice. Hypertens Res 35:213–220CrossRefPubMedPubMedCentral

25.

Lee WC, Chen HC, Wang CY, Lin PY, Ou TT et al (2010) Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB. Biosci Biotechnol Biochem 74:1355–1361CrossRefPubMed

26.

Hamden K, Carreau S, Jamoussi K, Miladi S, Lajmi S et al (2009) 1Alpha,25 dihydroxyvitamin D3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. J Nutr Sci Vitaminol (Tokyo) 55:215–222CrossRef

27.

Del Pino-Montes J, Benito GE, Fernández-Salazar MP, Coveñas R, Calvo JJ et al (2004) Calcitriol improves streptozotocin-induced diabetes and recovers bone mineral density in diabetic rats. Calcif Tissue Int 75:526–532CrossRefPubMed

28.

Baeke F, Van Belle TL, Takiishi T, Ding L, Korf H et al (2012) Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes. Diabetologia 55:2723–2732CrossRefPubMed

29.

Skyler JS (2013) Primary and secondary prevention of Type 1 diabetes. Diabet Med 30:161–169CrossRefPubMedPubMedCentral

30.

Deb DK, Sun T, Wong KE, Zhang Z, Ning G et al (2010) Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 77:1000–1009CrossRefPubMed

31.

Esteghamati A, Aryan Z, Esteghamati A, Nakhjavani M (2014) Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: Associations with inflammatory and cardiometabolic markers in 4391 subjects. Diabetes Metab 40:347–355PubMed

32.

Raab J, Giannopoulou EZ, Schneider S, Warncke K, Krasmann M et al (2014) Prevalence of vitamin D deficiency in pre-type 1 diabetes and its association with disease progression. Diabetologia 57:902–908CrossRefPubMed

33.

Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Yakout SM et al (2014) Lower vitamin D status is more common among Saudi adults with diabetes mellitus type 1 than in non-diabetics. BMC Public Health 14:153CrossRefPubMedPubMedCentral

Titel: Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress
verfasst von: X. Deng
J. Cheng
M. Shen
Publikationsdatum: 01.06.2016
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 6/2016
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0414-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Adaptability of structured forms for CSII initiation in patients with type 2 diabetes the Getting2GoalSM concept

Maternal obesity and malnourishment exacerbate perinatal oxidative stress resulting in diabetogenic programming in F1 offspring

Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans

A specific prediction equation is necessary to estimate peak oxygen uptake in obese patients with metabolic syndrome

Identification of a novel LEMD3 Y871X mutation in a three-generation family with osteopoikilosis and review of the literature